PCM
GANX icon

Potomac Capital Management’s Gain Therapeutics GANX Stock Holding History

Potomac Capital Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Sell
946,400
-62,200
-6% -$115K 1.31% 20
2026
Q1 		$1.96M Sell
1,008,600
-1,400
-0.1% -$3.05K 1.7% 15
2025
Q4 		$3.25M Buy
+1,010,000
New +$2.7M 2.61% 11

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Potomac Capital Management's GANX Position: Q2 2026 in Review

Potomac Capital Management reduced its Gain Therapeutics (GANX) stake by 6.2% in Q2 2026, selling an estimated $115K and leaving 946,400 shares worth $1.92M. The position accounts for 1.31% of the portfolio, ranked #20.

Potomac Capital Management first reported a position in GANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.25M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Potomac Capital Management held 946,400 shares of Gain Therapeutics worth $1.92M as of Q2 2026.
  • Potomac Capital Management sold 62,200 Gain Therapeutics shares in Q2 2026, an estimated $115K.
  • Gain Therapeutics made up 1.31% of Potomac Capital Management's portfolio in Q2 2026, its #20 holding.
  • Potomac Capital Management first reported a position in Gain Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Potomac Capital Management's Gain Therapeutics position peaked at $3.25M in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Potomac Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.